FDA Approves Copanlisib for Relapsed Indolent Follicular Lymphoma

New York, NY (September 14, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of copanlisib to treat patients with relapsed indolent follicular lymphoma (FL). The PI3K dual-isoform inhibitor, developed by Bayer, has been approved following the results of a phase II CHRONOS-1 trial, measuring results in a variety non-Hodgkin lymphoma (NHL) patients. The drug, which showed improved outcomes across a variety of slow-growing lymphoma subtypes, received priority review from the FDA in May 2017 for the treatment of relapsed follicular lymphoma patients who have received at least two prior therapies.

“Today’s approval of copanlisib marks an important advance in the development of new treatment options for adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.

“This approval provides another option for patients; we commend the patients and investigators who enable research such as this to continue to push forward to ultimately move closer to finding a cure.”

For more on the FDA approval of copanlisib, read the FDA press announcement here.

For additional information on follicular lymphoma, visit www.focusonfl.org.

About the Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services. To date, LRF has awarded nearly $60 million in lymphoma-specific research. For additional information on LRF’s research, education and services, visit lymphoma.org.

Jake DiGregorio